Old Web
English
Sign In
Acemap
>
authorDetail
>
Tae Y. Kim
Tae Y. Kim
Seoul National University
Dalotuzumab
Cetuximab
KRAS
Medicine
Irinotecan
2
Papers
51
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
2017
International Journal of Cancer
Francesco Sclafani
Tae Y. Kim
David Cunningham
Tae W. Kim
Josep Tabernero
Hans J. Schmoll
JaeKyung Roh
Sun Young Kim
Young Suk Park
Tormod Kyrre Guren
Eliza A. Hawkes
Stephen Clarke
David Ferry
Jan Erik Frödin
Mark Ayers
Michael Nebozhyn
Clare Peckitt
Andrey Loboda
David Watkins
Show All
Source
Cite
Save
Citations (3)
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
2015
Journal of the National Cancer Institute
Francesco Sclafani
Tae Y. Kim
David Cunningham
Tae W. Kim
Josep Tabernero
Hans J. Schmoll
JaeKyung Roh
Sun Young Kim
Young Soo Park
Tormod Kyrre Guren
Eliza A Hawkes
Steven J. Clarke
David Ferry
Jan Erik Frödin
Mark Ayers
Michael Nebozhyn
Clare Peckitt
Andrey Loboda
David J. Mauro
David Watkins
Show All
Source
Cite
Save
Citations (48)
1